TRAVERE THERAPEUTICS, INC. Net Income (Loss) Attributable to Parent, Diluted
TRAVERE THERAPEUTICS, INC. (TVTX) reported Net Income (Loss) Attributable to Parent, Diluted of -$102.68 million for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-26.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToParentDiluted · last filed 2019-02-26
- TRAVERE THERAPEUTICS, INC. net income (loss) attributable to parent, diluted for the quarter ending 2018-03-31 was -$18.38M.
- TRAVERE THERAPEUTICS, INC. net income (loss) attributable to parent, diluted for the quarter ending 2017-12-31 was -$17.62M.
- TRAVERE THERAPEUTICS, INC. net income (loss) attributable to parent, diluted for the quarter ending 2017-09-30 was -$17.79M.
- TRAVERE THERAPEUTICS, INC. net income (loss) attributable to parent, diluted for the quarter ending 2017-06-30 was -$13.23M.
- TRAVERE THERAPEUTICS, INC. net income (loss) attributable to parent, diluted for fiscal 2018 was -$102.68M.
- TRAVERE THERAPEUTICS, INC. net income (loss) attributable to parent, diluted for fiscal 2017 was -$59.73M.
- TRAVERE THERAPEUTICS, INC. net income (loss) attributable to parent, diluted for fiscal 2016 was -$49.56M, a 141.60% decline from fiscal 2015.
- TRAVERE THERAPEUTICS, INC. net income (loss) attributable to parent, diluted for fiscal 2015 was $119.12M.
| Period end | Net Income (Loss) Attributable to Parent, Diluted 3 month | Net Income (Loss) Attributable to Parent, Diluted 3 month as first filed | Net Income (Loss) Attributable to Parent, Diluted 6 month | Net Income (Loss) Attributable to Parent, Diluted 9 month | Net Income (Loss) Attributable to Parent, Diluted 12 month |
|---|---|---|---|---|---|
| 2018-12-31 | -$102.68M 10-K · filed 2019-02-26 | ||||
| 2018-03-31 | -$18.38M 10-Q · filed 2018-07-06 | -$36.00M derived: sum of 2 quarters · filed 2019-02-26 | -$53.79M derived: sum of 3 quarters · filed 2019-02-26 | -$67.02M derived: sum of 4 quarters · filed 2019-02-26 | |
| 2017-12-31 | -$17.62M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | -$35.41M derived: sum of 2 quarters · filed 2019-02-26 | -$48.64M derived: sum of 3 quarters · filed 2019-02-26 | -$59.73M 10-K · filed 2019-02-26 | |
| 2017-09-30 | -$17.79M 10-Q · filed 2017-11-07 | -$31.02M derived: sum of 2 quarters · filed 2017-11-07 | -$42.11M 10-Q · filed 2017-11-07 | -$53.63M derived: sum of 4 quarters · filed 2019-02-26 | |
| 2017-06-30 | -$13.23M 10-Q · filed 2017-08-09 | -$24.32M 10-Q · filed 2017-08-09 | -$35.84M derived: sum of 3 quarters · filed 2019-02-26 | -$72.95M derived: sum of 4 quarters · filed 2019-02-26 | |
| 2017-03-31 | -$12.35M 10-Q · filed 2018-07-06 | -$22.61M derived: sum of 2 quarters · filed 2019-02-26 | -$59.72M derived: sum of 3 quarters · filed 2019-02-26 | -$73.12M derived: sum of 4 quarters · filed 2019-02-26 | |
| 2016-12-31 | -$10.26M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | -$47.37M derived: sum of 2 quarters · filed 2019-02-26 | -$60.77M derived: sum of 3 quarters · filed 2019-02-26 | -$49.56M 10-K · filed 2019-02-26 | |
| 2016-09-30 | -$37.11M 10-Q · filed 2017-11-07 | -$50.52M derived: sum of 2 quarters · filed 2017-11-07 | -$39.30M 10-Q · filed 2017-11-07 | -$55.78M derived: sum of 4 quarters · filed 2018-07-06 | |
| 2016-06-30 | -$13.40M 10-Q · filed 2017-08-09 | -$7.46M 10-Q · filed 2017-08-09 | -$18.67M derived: sum of 3 quarters · filed 2018-07-06 | $57.44M derived: sum of 4 quarters · filed 2018-07-06 | |
| 2016-03-31 | -$3.12M 10-Q · filed 2017-05-05 | -$5.26M derived: sum of 2 quarters · filed 2018-07-06 | $70.84M derived: sum of 3 quarters · filed 2018-07-06 | $45.31M derived: sum of 4 quarters · filed 2018-07-06 | |
| 2015-12-31 | -$2.14M derived: 10-K 12 month − 10-Q 9 month · filed 2018-07-06 | $73.96M derived: sum of 2 quarters · filed 2018-07-06 | $48.44M derived: sum of 3 quarters · filed 2018-07-06 | $119.12M 10-K · filed 2018-07-06 | |
| 2015-09-30 | $76.11M 10-Q · filed 2016-11-04 | $50.58M derived: sum of 2 quarters · filed 2016-11-04 | $121.26M 10-Q · filed 2016-11-04 | $61.72M derived: sum of 4 quarters · filed 2017-03-01 | |
| 2015-06-30 | -$25.53M 10-Q · filed 2016-08-05 | $25.53M 10-Q · filed 2015-08-10 | $15.16M 10-Q · filed 2016-08-05 | -$14.38M derived: sum of 3 quarters · filed 2017-03-01 | -$38.05M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $40.17M 10-Q · filed 2016-05-05 | $11.15M derived: sum of 2 quarters · filed 2017-03-01 | -$12.52M derived: sum of 3 quarters · filed 2017-03-01 | -$33.70M derived: sum of 4 quarters · filed 2017-03-01 | |
| 2014-12-31 | -$29.03M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | -$52.70M derived: sum of 2 quarters · filed 2017-03-01 | -$73.87M derived: sum of 3 quarters · filed 2017-03-01 | -$110.94M 10-K · filed 2017-03-01 | |
| 2014-09-30 | -$23.67M 10-Q · filed 2015-11-06 | -$25.25M 10-Q · filed 2014-11-13 | -$44.84M derived: sum of 2 quarters · filed 2015-11-06 | -$81.91M 10-Q · filed 2015-11-06 | |
| 2014-06-30 | -$21.17M 10-Q · filed 2015-08-10 | ||||
| 2013-12-31 | -$34.63M 10-K · filed 2016-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |